Navigation Links
QRxPharma to Sponsor Symposium at 13th World Congress on Pain Meeting
Date:8/31/2010

SYDNEY and BEDMINSTER, N.J., Aug. 31 /PRNewswire/ -- QRxPharma (ASX: QRX and OTCQX: QRXPY) announced today it will sponsor a symposium at the 13th World Congress of Pain on 31 August, 2010 at Palais des congres de Montreal.  The symposium, titled "Dual Opioid Therapy: Changing the Paradigm" will focus on preclinical and clinical data for MoxDuo®IR, an immediate-release Dual Opioid product for moderate to severe acute pain.  Featured speakers who will highlight Dual Opioids at this symposium are internationally recognised pain experts, Drs. Nicholson, Pasternak and Webster.

In addition to the symposium, QRxPharma was invited to present three posters on September 2, from 9:30-10:30 with the results from MoxDuo IR comparative trials:

  • "Morphine Equivalent Doses of Dual Opioid Treatment With Morphine Plus Oxycodone Versus Morphine and Oxycodone Monotherapy for Post-Operative Pain: Safety and Analgesic Profiles"
  • "Treatment of Post-Operative Pain With a Dual Opioid Combination of Morphine and Oxycodone: Analgesia and Side Effects"
  • "An Active Controlled Evaluation of the Efficacy and Safety of Dual Opioid Treatment With Morphine Plus Oxycodone for Acute Pain Following Total Knee Arthroplasty"

In the recently completed Phase 3 Combination Rule Study, MoxDuo IR demonstrated both a statistically superior analgesic effect compared to morphine and oxycodone alone as well as a favourable side effect profile despite delivering twice the opioid dose of its individual components.  The Company is currently completing its final Phase 3 registration trial for MoxDuo IR in patients who have undergone total knee replacement surgery.

When compared to other opioids at equi-analgesic doses, MoxDuo IR reduced the occurrence rate and intensity of moderate to severe nausea, vomiting and dizziness by 50-75% or more (study 021) and demonstrated when such Adverse Events (AEs) do occu
'/>"/>

SOURCE QRxPharma
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. QRxPharma Doses First Patients in Phase III Clinical Trial Program for its Dual Opioid Pain Therapy
2. QRxPharma Releases Successful Phase 3 Study Results for Dual Opioid Pain Therapy
3. QRxPharma Releases Additional Phase 3 Data for Q8003IR Dual Opioid Pain Therapy
4. QRxPharma Successfully Completes Comparative Study for Dual-Opioid(TM) Pain Therapy
5. QRxPharma Inks Deal with Patheon for the Manufacture of MoxDuo(TM)CR
6. QRxPharma Limited Announces A$21.6 Million Fully Underwritten Capital Raising
7. QRxPharma Initiates Second Pivotal Phase 3 Study of MoxDuo(TM)IR Dual-Opioid(TM) for NDA Submission
8. QRxPharma Limited and China Aoxing Pharmaceutical Company Announce Strategic Alliance for Development of MoxDuo(R)IV
9. QRxPharma Releases Additional Pivotal Phase 3 Combination Rule Study Data for MoxDuo(R)IR in Patients with Post-Surgical Pain
10. QRxPharma Successfully Completes Comparative Phase 1 Proof-of-Concept Study for MoxDuo(R) CR Tablet Formulation
11. QRxPharma Receives Positive Feedback from Scientific Advice Meetings in Europe on MoxDuo®IR Development and Registration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... -- , Extensively hydrolyzed milk formula with LGG ... Cow milk protein allergy (CMPA) is the leading cause of food ... has been managed by eliminating milk proteins from a ... is possible to help build of oral tolerance to ... the first year of life by using an extensively ...
(Date:10/30/2014)... , Oct. 29, 2014 nebulizer is a ... (asthma, COPD and cystic fibrosis) that converts liquid medication ... reach into the lungs of a patient when inhaled ... nebulizers market is dominated by various devices powered by ... prevalence of asthma, COPD and cystic fibrosis and growing ...
(Date:10/30/2014)... LOS ANGELES , Oct. 29, 2014 /PRNewswire/ ... pharmaceutical company devoted to bringing new products to ... 2015. ViaDerma has developed an innovative, ... for rapid mass transfer of pharmaceutical active ingredients ... to provide immediate localized therapy. The transdermal delivery ...
Breaking Medicine Technology:Experts Present Latest Research at Allergy Day 2Experts Present Latest Research at Allergy Day 3Nebulizers Market (Pneumatic Nebulizers, Ultrasonic Nebulizers and Mesh Nebulizers) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019 2Nebulizers Market (Pneumatic Nebulizers, Ultrasonic Nebulizers and Mesh Nebulizers) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019 3ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 2ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 3
... at American College of Rheumatology Annual Congress -, ... BMY ) today announced the results of ... that showed ORENCIA(R) (abatacept) improved daily,activity participation, such ... and sleep quality in adult rheumatoid arthritis,(RA) patients ...
... Ophthalmology Annual Meeting Describes ... in Treatment of Endothelial Disease, NEW ORLEANS, Nov. ... Academy of Ophthalmology,s Annual Meeting, Massimo Busin,MD, department head ... Italy, described a technique that significantly improved,results in patients ...
Cached Medicine Technology:Post-Hoc Data Show Daily Activity Participation, Independence and Sleep Quality Improved in Adults with Moderate to Severe Rheumatoid Arthritis After Treatment with ORENCIA(R) (Abatacept) 2Post-Hoc Data Show Daily Activity Participation, Independence and Sleep Quality Improved in Adults with Moderate to Severe Rheumatoid Arthritis After Treatment with ORENCIA(R) (Abatacept) 3Post-Hoc Data Show Daily Activity Participation, Independence and Sleep Quality Improved in Adults with Moderate to Severe Rheumatoid Arthritis After Treatment with ORENCIA(R) (Abatacept) 4Post-Hoc Data Show Daily Activity Participation, Independence and Sleep Quality Improved in Adults with Moderate to Severe Rheumatoid Arthritis After Treatment with ORENCIA(R) (Abatacept) 5Post-Hoc Data Show Daily Activity Participation, Independence and Sleep Quality Improved in Adults with Moderate to Severe Rheumatoid Arthritis After Treatment with ORENCIA(R) (Abatacept) 6Post-Hoc Data Show Daily Activity Participation, Independence and Sleep Quality Improved in Adults with Moderate to Severe Rheumatoid Arthritis After Treatment with ORENCIA(R) (Abatacept) 7Post-Hoc Data Show Daily Activity Participation, Independence and Sleep Quality Improved in Adults with Moderate to Severe Rheumatoid Arthritis After Treatment with ORENCIA(R) (Abatacept) 8Post-Hoc Data Show Daily Activity Participation, Independence and Sleep Quality Improved in Adults with Moderate to Severe Rheumatoid Arthritis After Treatment with ORENCIA(R) (Abatacept) 9Improved Cornea Surgery Technique Provides Enhanced Transplant Success 2
(Date:10/30/2014)... Graphics, coding, typography and search engine optimization– ... of web design and require thorough knowledge to create ... to create a website can be as easy as ... reviews and Facebook posts all accumulate on a multiple ... evolution of how a business can develop a website," ...
(Date:10/30/2014)... (PRWEB) October 30, 2014 Paramount Rx, ... care, is increasing efforts to help people save money ... continue to increase for prescription drugs in the new ... savings and resources to bridge the relationship between consumers, ... of the biggest challenges people face today with medical ...
(Date:10/30/2014)... 2014 Home Care Assistance – Halton/Peel ... non-medical, in-home senior care, is weighing in on a ... , The study, performed by the University of Illinois, ... 78 over a week-long period and observed how much ... activity. By examining the structural soundness of the white ...
(Date:10/30/2014)... Newport Beach, California (PRWEB) October 30, 2014 ... superfood nutrtion bars are now available through a unique ... an online site designed to empower the everyday athlete. ... the worlds best athletes and created a system to ... really excited to see REV’D® is now available on ...
(Date:10/30/2014)... 2014 (HealthDay News) -- When it comes to heart disease, ... to delay care when they have symptoms that spell trouble. ... the hospital with a more severe or advanced stage of ... author Catherine Kreatsoulas, a Fulbright Scholar and research fellow at ... release from the Heart and Stroke Foundation of Canada. ...
Breaking Medicine News(10 mins):Health News:Facebook Websites In Thirty-Seconds 2Health News:Paramount Rx Discount Card Program Provides Valuable Resources in Midst of Current Health Care Reform 2Health News:Paramount Rx Discount Card Program Provides Valuable Resources in Midst of Current Health Care Reform 3Health News:Home Care Assistance – Halton/Peel Region, a Top Provider of In-Home Care, Responds to Study Linking Exercise to Healthier Senior Brains 2Health News:Home Care Assistance – Halton/Peel Region, a Top Provider of In-Home Care, Responds to Study Linking Exercise to Healthier Senior Brains 3Health News:Nutrition Experts at TheFeed.com Get REV'D 2Health News:Nutrition Experts at TheFeed.com Get REV'D 3Health News:Women Often Ignore Signs of Heart Trouble 2
... action for the public, health professionals, the food industry and ... sodium (salt) Americans consume daily. , In an advisory, ... , the association sets out the science behind the American ... consume no more than 1500 milligrams (mg) of sodium a ...
... HealthDay Reporter , THURSDAY, Jan. 13 (HealthDay News) -- ... "Together We Thrive: Tucson and America" memorial, President Barack Obama ... visit with her and her husband Mark Kelly at University ... An aide to House Minority Leader Nancy Pelosi (D-Calif.) ...
... plenty of natural light and artwork may seem like unaffordable ... and design features can improve patient care and in the ... elements of the "Fable hospital," an ideal health care facility ... design. Elements of the Fable hospital are being adopted on ...
... motion in living cells may help researchers shed light ... according to Ning Fang, an associate scientist at the ... at Iowa State University. ... in Engineered Environments and Live Cells with Gold Nanorods ...
... shows that oncolytic viruses, which are engineered to destroy ... brain tumors if equipped with an enzyme that helps ... the cancer-killing virus clear its way through the thickets ... impede the virus,s movement through the tumor, say researchers ...
... -- Bottle rockets can cause serious eye injuries to children ... warns. Researchers at Vanderbilt University Medical Center in Nashville, ... aged 18 or younger, who suffered eye injuries caused by ... patients were injured while launching bottle rockets and two were ...
Cached Medicine News:Health News:Population-wide reduction in salt consumption recommended 2Health News:Population-wide reduction in salt consumption recommended 3Health News:Giffords Opens Eyes. Like 'Watching a Miracle,' Friends Say 2Health News:Giffords Opens Eyes. Like 'Watching a Miracle,' Friends Say 3Health News:Next-generation hospital design can improve health -- and save money 2Health News:New tool for cell research may help unravel secrets of disease 2Health News:Virus might fight brain tumors better if armed with bacterial enzyme, study shows 2Health News:Bottle Rockets Can Cause Serious Eye Injuries in Kids 2
Provides stable positioning of a patient during hip surgery. Multi-adjustment arms allow the positioner to be adjusted to fit all sizes of patients. Especially helpful with large patients where reach...
Interphlex Flexible Stablization Rods offer correction of Hammer Toes with a High level of Flexibility while maintaining correct toe length and shape....
The Continuous Wave II Arthroscopy Pump provides pulse-free, continuous fluid inflow for joint distention when used in conjunction with a high flow sheath or separate inflow cannula....
True/Fix Distal Femoral Nail System...
Medicine Products: